Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

313 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High-Resolution Maps of Material Stocks in Buildings and Infrastructures in Austria and Germany.
Haberl H, Wiedenhofer D, Schug F, Frantz D, Virág D, Plutzar C, Gruhler K, Lederer J, Schiller G, Fishman T, Lanau M, Gattringer A, Kemper T, Liu G, Tanikawa H, van der Linden S, Hostert P. Haberl H, et al. Among authors: schiller g. Environ Sci Technol. 2021 Mar 2;55(5):3368-3379. doi: 10.1021/acs.est.0c05642. Epub 2021 Feb 18. Environ Sci Technol. 2021. PMID: 33600720 Free PMC article.
ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study.
Maris M, Salles G, Kim WS, Kim TM, Lyons RM, Arellano M, Karmali R, Schiller G, Cull E, Abboud CN, Batlevi C, Kagiampakis I, Rebelatto MC, Lee Y, Kirby LC, Wang F, Bothos J, Townsley DM, Fathi AT, Ribrag V. Maris M, et al. Among authors: schiller g. Target Oncol. 2024 Apr 29. doi: 10.1007/s11523-024-01054-z. Online ahead of print. Target Oncol. 2024. PMID: 38683495
A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia.
Levis MJ, Perl AE, Schiller GJ, Fathi AT, Roboz GJ, Wang ES, Altman JK, Rajkhowa T, Ando M, Suzuki T, Subach RA, Maier G, Madden T, Johansen M, Cheung K, Kurman M, Smith CC. Levis MJ, et al. Among authors: schiller gj. Blood Adv. 2024 Mar 19:bloodadvances.2023010619. doi: 10.1182/bloodadvances.2023010619. Online ahead of print. Blood Adv. 2024. PMID: 38502195
Acute Pulmonary Injury in Hematology Patients Supported with Pathogen Reduced and Conventional Platelet Components.
Wheeler AP, Snyder EL, Refaai MA, Cohn CS, Poisson J, Fontaine MJ, Sehl M, Nooka AK, Uhl L, Spinella PC, Fenelus M, Liles DK, Coyle T, Becker J, Jeng MR, Gehrie EA, Spencer BR, Young PP, Johnson AD, O'Brien J, Schiller GJ, Roback JD, Malynn E, Jackups R, Avecilla S, Liu K, Bentow S, Varrone J, Benjamin RJ, Corash L. Wheeler AP, et al. Among authors: schiller gj. Blood Adv. 2024 Mar 6:bloodadvances.2023012425. doi: 10.1182/bloodadvances.2023012425. Online ahead of print. Blood Adv. 2024. PMID: 38447116
Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results.
Yacoub A, Borate U, Rampal RK, Ali H, Wang ES, Gerds AT, Hobbs G, Kremyanskaya M, Winton E, O'Connell C, Goel S, Oh ST, Schiller G, McCloskey J, Palmer J, Holmes H, Hager S, Assad A, Erickson-Viitanen S, Zhou F, Daver N. Yacoub A, et al. Among authors: schiller g. Blood Adv. 2024 Mar 26;8(6):1515-1528. doi: 10.1182/bloodadvances.2023011620. Blood Adv. 2024. PMID: 38290135 Free PMC article. Clinical Trial.
Inhibition of Ephrin B2 Reverse Signaling Abolishes Multiple Myeloma Pathogenesis.
Sasine JP, Kozlova NY, Valicente L, Dukov J, Tran DH, Himburg HA, Kumar S, Khorsandi S, Chan A, Grohe S, Li M, Kan J, Sehl ME, Schiller GJ, Reinhardt B, Singh BK, Ho R, Yue P, Pasquale EB, Chute JP. Sasine JP, et al. Among authors: schiller gj. Cancer Res. 2024 Mar 15;84(6):919-934. doi: 10.1158/0008-5472.CAN-23-1950. Cancer Res. 2024. PMID: 38231476 Free PMC article.
313 results